Study on Immunotherapy Combinations for Patients with Metastatic Non-Small Cell Lung Cancer

Sponsor: Gilead Sciences

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT05676931

Provider View

This clinical trial is testing the effectiveness and safety of combining different immunotherapy treatments for patients with advanced non-small cell lung cancer (NSCLC) that has spread to other parts of the body.

Patient Parameters

Program Overview

The aim of this study is to evaluate how well a combination of immunotherapy treatments works in shrinking tumors in patients with metastatic non-small cell lung cancer (NSCLC). The study will also assess the safety and how well patients tolerate these treatments.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of Stage IV metastatic non-small cell lung cancer (NSCLC).
  • Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
  • Have at least one tumor that can be measured using standard criteria.
  • Have good organ and bone marrow function as determined by specific medical tests.
  • Be willing to provide a sample of tumor tissue for the study.

Exclusion Criteria

  • Have medical conditions that could make the study treatments unsafe, according to the study doctor.
  • Have received any live vaccines within 28 days before starting the study treatments.
  • Have a chronic medical condition that requires high doses of steroids or other medications that suppress the immune system.
  • Have psychiatric or substance abuse issues that could interfere with participating in the study.
  • Have an active autoimmune disease or a history of autoimmune disease that required treatment in the past two years, except for vitiligo or resolved childhood asthma or allergies.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.